Why We Do It
We are invested in making a meaningful difference in the lives of patients and their families around the globe.
We do this by advancing innovative solutions for clinical practice that are sustainable, cost-effective and accessible.
“We wouldn’t be alive today without Fogarty Innovation.”
– Company-In-Residence CEO
At our core…
We behave with integrity first and foremost, knowing we affect the lives of patients and their loved ones.
We put team before self, valuing mutual trust and respect for each other, and sharing a foundational belief that strong teams enhance performance.
We believe in equality and seek diversity to keep growing as a team — not only in race and gender, but also in expression.
We value continuous learning, both as teachers and perpetual students.
We believe the process of innovation is a discipline that can be taught and honed.
We trust in the power of an audacious vision because it taps into a basic human desire: belonging to and believing in something bigger than ourselves.
We have a sense of wonder and a spirit of adventure as we push boundaries to create positive impact on the global medical ecosystem.
We stay humble for all that remains to be done in shaping the future of human health.
We believe these things because we have seen the power of their impact
Chronus Health, FII’s Newest Company, Poised to Revolutionize $80 Billion U.S. Clinical Laboratory Testing Market
Imagine going to the doctor’s office for your annual check-up. The nurse starts going through the usual tests, such as measuring your blood pressure, heart rate and temperature and completing the blood draw from your arm. Then the nurse immediately starts testing your...
Fogarty Institute graduate Alydia Health, formerly known as InPress Technologies, is well on its way to conducting a pivotal study, thanks to the closing of a recent $10M Series B round led by Global Health Investment Fund. The U.S. study aims to prove the safety and...
As the first and only device cleared by the FDA to collect cells from the fallopian tubes, the Mako 7 device, originally developed by nVision, a Fogarty Institute graduate, offers a potential platform for earlier detection of ovarian cancer. The company was recently...